/0 /1 /2 /3 /1 /2 /0 /4 /i255 /6 /7 /8 /9 /i255 /10 /11/10 /12 /13 /14 /13 /15 /13 /16 /17
/18 /14 /14 /19 /17 /7 /1 /1 /20 /15 /17 /21 /22 /23 /20 /24 /16 /25 /22 /15 /13 /1 /19 /12 /13 /14 /13 /15 /13 /16 /17 /1 /19 /12 /13 /14 /13 /15 /13 /16 /17 /1 /26 /0 /27 /3 /28 /28 /9 /29 /3 /21 /8 /30 /6 /26 /8 /8 /0 /29 /2 /26 /2 /9 /31 /2 /1 /15 /13 /12 /12 /28 /17 /19 /13 /32 /21 /28 /32 /15 /28 /1 /26 /0 /15 /6 /28 /31 /3 /33 /24 /33 /31 /26 /9 /29 /8 /8 /2 /27 /8 /29 /6 /28 /3 /33/6 /1 /2
/i255
/35 /36 /37 /38 /39 /i255 /40 /41 /42 /43 /36 /44 /45 /i255 /47 /36 /48 /49 /36 /41 /44 /i255 /50 /51 /37 /52 /i255 /53 /54 /53 /51
/i255
/55 /56 /39 /i255 /i255 /57 /58 /59 /60 /58 /61 /35 /62 /62 /45 /i255 /57 /58 /62 /40 /40 /60 /63 /56 /62
/i255
/56 /59 /64 /65 /i255 /66 /54 /50 /67 /68 /54 /45 /i255 /69 /38 /41 /70 /42 /71 /48 /i255 /50 /54 /i255 /42 /48 /i255 /72 /56 /59 /64
/i255
/58 /42 /37 /73 /38 /39 /i255 /74 /42 /48 /75 /76 /55 /39 /i255 /77 /78 /69 /56 /35 /79 /50 /67 /i255 /56 /48 /37 /38 /41 /80 /38 /48 /37 /42 /71 /48 /i255 /81 /71 /41 /i255 /49 /48 /43 /38 /41 /70 /38 /41 /80 /38 /43 /i255 /82 /71 /82 /49 /73 /36 /37 /42 /71 /48 /70 /i255 /82 /36 /41 /37 /42 /83 /42 /82 /36 /37 /42 /48 /84 /i255 /42 /48 /i255 /82 /36 /41 /38 /48 /37 /i255 /70 /37 /49 /43 /44 /i255 /55 /41 /71 /44 /38 /83 /37 /71 /i255 /74 /36 /i255 /40 /41 /71 /48 /37 /38 /41 /36
/i255
/58 /44 /82 /38 /39 /i255 /59 /38 /48 /38 /85/38 /43
/i255
/59 /38 /80 /42 /38 /85/39 /i255 /40 /49 /73 /73 /i255 /64 /71 /36 /41 /43 /i255 /86 /44 /i255 /56 /59 /64 /i255 /60 /i255 /87 /56 /59 /64 /54 /54 /54 /54 /54 /51 /68 /88 /89
/i255
/35 /38 /83 /42 /70 /42 /71 /48 /39 /i255 /58 /52 /49 /41 /70 /43 /36 /44 /45 /i255 /47 /36 /48 /49 /36 /41 /44 /i255 /50 /53 /37 /52 /i255 /53 /54 /53 /51 /45 /i255 /80 /36 /73 /42 /43 /i255 /37 /52 /41 /71 /49 /84 /52 /i255 /50 /50 /39 /68 /67 /i255 /82 /90/i255 /87 /55 /36 /83 /42 /81 /42 /83 /89 /i255 /91/71 /48 /43 /36 /44 /45 /i255 /40 /38 /86 /41 /49 /36 /41 /44 /i255 /68 /37 /52 /i255 /53 /54 /53 /88
/i255
/i255/92 /93 /94 /i255 /96
/97 /98 /99 /94 /i255 /100 /94 /99 /101 /94 /102 /i255 /101 /103 /i255 /104 /98 /105/106 /107 /94 /108 /94 /i255 /102 /101 /108 /93 /i255 /108 /93 /94 /i255 /109 /98 /107 /107 /98 /102 /101 /110 /111 /i255 /98 /112 /108 /104 /98 /105/94 /103 /113
/i255
/52 /37 /37 /82 /70 /39 /114 /114 /86 /73 /42 /48 /75 /115 /49 /83 /70 /43 /115 /38 /43 /49 /114 /70 /82 /71 /48 /70 /71 /41 /114 /41 /83 /42 /114 /83 /73 /42 /48 /42 /83 /36 /73 /79 /37 /41 /42 /36 /73 /70 /115 /52 /37 /90/73
 /83 /37 /84 /71 /80 /116/49 /83 /70 /43 /115 /38 /43 /49
/i255
/92 /93 /94 /i255 /109 /98 /107 /107 /98 /102 /101 /110 /111 /i255 /96 /108 /108 /96 /104 /93 /105/94 /110 /108 /103 /i255 /96 /100 /94 /i255 /96 /106 /106 /100 /98 /99 /94 /117 /i255 /98 /100 /i255 /96 /104 /118 /110 /98 /102 /107 /94 /117 /111 /94 /117 /i255 /96 /103 /i255 /106 /96 /100 /108 /i255 /98 /109 /i255 /108 /93 /101 /103 /i255 /100 /94 /99 /101 /94 /102 /113
/i255
/119 /120 /121 /122 /121 /123 /121 /124 /125
/0 /1 /2 /3 /1 /2 /0 /4 /i255 /6 /7 /8 /9 /i255 /10 /11/10 /12 /13 /14 /13 /15 /13 /16 /17
/18 /14 /14 /19 /17 /7 /1 /1 /20 /15 /17 /21 /22 /23 /20 /24 /16 /25 /22 /15 /13 /1 /19 /12 /13 /14 /13 /15 /13 /16 /17 /1 /19 /12 /13 /14 /13 /15 /13 /16 /17 /1 /26 /0 /27 /3 /28 /28 /9 /29 /3 /21 /8 /30 /6 /26 /8 /8 /0 /29 /2 /26 /2 /9 /31 /2 /1 /15 /13 /12 /12 /28 /17 /19 /13 /32 /21 /28 /32 /15 /28 /1 /26 /0 /15 /6 /28 /31 /3 /33 /24 /33 /31 /26 /9 /29 /8 /8 /2 /27 /8 /29 /6 /28 /3 /33/2 /1 /2/34 /35 /36 /37 /38 /39 /35 /36 /40 /41 /42 /43 /41 /36 /40 /35 /44 /36 /45 /42 /41 /46 /41 /47 /42 /48 /49 /45 /39 /34 /47 /36 /45 /50 /51 /52 /53 /51 /52 /53 /50 /53 /53
/54 /55 /56 /57 /58 /52 /59 /60 /54 /61/39 /62 /60 /63 /60 /54 /60 /55/42 /56 /64 /65 /66 /56 /59 /i255 /42 /56 /66 /56 /57 /62 /54 /68 /i255 /39 /55 /57 /58 /i255 /69 /48 /55 /56 /57 /58 /70
/42 /56 /64 /65 /66 /56 /59 /45 /42 /57 /59 /61 /71 /38 /39 /45 /35 /58 /63 /56 /62 /64 /56 /58 /63 /65 /60 /58 /45 /i255 /35 /48 /72 /45 /41 /58 /73 /55 /65 /66 /68 /45 /50 /51 /52 /53 /51 /52 /53 /50 /53 /53
/54 /55 /56 /57 /58 /52 /74 /59 /75/35 /58 /75 /60 /62 /76/56 /59
/48 /60 /58 /66 /56 /58 /63 /77 /39 /57 /62 /56 /58 /63 /57 /55
/39 /56 /62 /76/65 /66 /66 /65 /60 /58/42 /56 /64 /65 /66 /56 /59 /i255 /41 /58 /73 /55 /65 /66 /68 /i255 /35 /48 /72 /i255 /69 /48 /55 /56 /57 /58 /70
/42 /56 /64 /65 /66 /56 /59 /i255 /42 /57 /59 /61 /71 /38 /39 /45 /35 /58 /63 /56 /62 /64 /56 /58 /63 /65 /60 /58 /45
/35 /48 /72 /45 /46 /74 /57 /58 /65 /66 /68 /45 /50 /53 /52 /50 /78 /52 /53 /50 /53 /53 /45 /54 /55 /56 /57 /58 /52 /74 /59 /75/35 /58 /75 /60 /62 /76/56 /59
/48 /60 /58 /66 /56 /58 /63 /77 /39 /57 /62 /56 /58 /63 /57 /55/39 /56 /62 /76/65 /66 /66 /65 /60 /58/42 /56 /64 /65 /66 /56 /59 /i255 /46 /74 /57 /58 /65 /66 /68 /i255 /35 /48 /72 /i255 /69 /40 /62 /57 /58 /66 /55 /57 /63 /56 /59 /i255 /79 /80 /i255 /47 /55 /65 /54 /65 /57 /i255 /49 /57 /62 /64 /56 /80 /71 /43 /56 /62 /57 /52 /i255 /39 /35 /i255 /57 /63 /63 /56 /66 /63 /66 /i255 /63 /60 /i255 /63 /68
/56
/57 /54 /54 /81 /62 /57 /54 /80 /i255 /60 /75 /i255 /68 /56 /62 /i255 /63 /62 /57 /58 /66 /55 /57 /63 /65 /60 /58 /i255 /66 /82 /65 /55 /55 /66 /70 /i255 /69 /48 /55 /56 /57 /58 /70
/83 /57 /63 /57 /i255 /46 /57 /75 /56 /63 /80 /i255 /57 /58 /59 /i255 /84/60 /58 /65 /63 /60 /62 /65 /58 /73 /i255 /85 /60 /57 /62 /59 /71 /34 /65 /58 /82 /38 /39 /i255 /86 /58 /57 /55 /71 /50 /87 /52 /88 /78 /52 /59 /60 /54 /61/44 /63 /68 /56 /62/83 /46 /84/85 /i255 /39 /55 /57 /58
/34 /35 /36 /37 /38 /39 /35 /36 /40 /41 /42 /43 /41 /36 /40 /35 /44 /36 /45 /42 /41 /46 /41 /47 /42 /48 /49 /45 /39 /34 /47 /36 /45 /50 /51 /52 /53 /51 /52 /53 /50 /53 /53 /52 /59 /60 /54 /61/39 /62 /60 /63 /60 /54 /60 /55/42 /56 /64 /65 /66 /56 /59 /i255 /42 /56 /66 /56 /57 /62 /54 /68 /i255 /39 /55 /57 /58 /i255 /69 /40 /62 /57 /54 /82 /56 /59 /i255 /48 /68 /57 /58 /73 /56 /66 /70
/42 /56 /64 /65 /66 /56 /59 /i255 /42 /57 /59 /61 /71 /38 /39 /45 /35 /58 /63 /56 /62 /64 /56 /58 /63 /65 /60 /58 /45
/35 /48 /72 /45 /46 /74 /57 /58 /65 /66 /68 /45 /50 /53 /52 /50 /78 /52 /53 /50 /53 /53 /45 /63 /62 /57 /54 /82 /56 /59 /45 /54 /68 /57 /58 /73 /56 /66 /52 /59 /60 /54/35 /58 /75 /60 /62 /76/56 /59
/48 /60 /58 /66 /56 /58 /63 /77 /39 /57 /62 /56 /58 /63 /57 /55
/39 /56 /62 /76/65 /66 /66 /65 /60 /58/42 /56 /64 /65 /66 /56 /59 /i255 /46 /74 /57 /58 /65 /66 /68 /i255 /35 /48 /72 /i255 /69 /40 /62 /57 /54 /82 /56 /59 /i255 /48 /68 /57 /58 /73 /56 /66 /70
/42 /56 /64 /65 /66 /56 /59 /45 /42 /57 /59 /61 /71 /38 /39 /45 /35 /58 /63 /56 /62 /64 /56 /58 /63 /65 /60 /58 /45 /i255 /35 /48 /72 /45 /41 /58 /73 /55 /65 /66 /68 /45 /50 /51 /52 /53 /51 /52 /53 /50 /53 /53 /52 /59 /60 /54/35 /58 /75 /60 /62 /76/56 /59
/48 /60 /58 /66 /56 /58 /63 /77 /39 /57 /62 /56 /58 /63 /57 /55
/39 /56 /62 /76/65 /66 /66 /65 /60 /58/42 /56 /64 /65 /66 /56 /59 /i255 /41 /58 /73 /55 /65 /66 /68 /i255 /35 /48 /72 /i255 /69 /40 /62 /57 /54 /82 /56 /59 /i255 /48 /68 /57 /58 /73 /56 /66 /70
/89 /90 /91 /92 /93 /94 /95 /91 /96 /97 /i255 /99 /100 /i255 /101 /102 /103 /91 /100 /99 /94 /90 /91 /102 /i255 /104 /102 /90 /i255 /105 /91 /93 /106 /99 /i255 /107 /i255 /108 /100 /100 /91 /109 /93 /i255 /99 /100 /i255 /110 /111 /112 /i255 /113 /114 /115/91 /90 /91 /95 /96 /94 /102 /96 /91 /99 /90
/116 /87 /50 /50 /i255 /117 /65 /55 /76/57 /58 /i255 /83 /62 /65 /64 /56 /118 /i255 /84/57 /65 /55 /i255 /48 /60 /59 /56 /i255 /50 /50 /87 /53 /i255 /107 /i255 /34 /57 /i255 /119 /60 /55 /55 /57 /118 /i255 /48 /47 /i255 /116 /53 /50 /116 /51 /71 /50 /50 /87 /53
/40 /56 /55 /120 /i255 /121 /87 /121 /71 /53 /78 /122 /71 /78 /123 /123 /123 /i255 /107 /i255 /41 /71 /76/57 /65 /55 /120 /i255 /65 /62 /79 /124/68 /56 /57 /55 /63 /68 /52 /81 /54 /66 /59 /52 /56 /59 /81 /i255 /107 /i255 /125/56 /79 /120 /i255 /65 /62 /79 /52 /81 /54 /66 /59 /52 /56 /59 /81
 
 
UCSD Human Research Protections Program  
New Biomedical Application  
RESEARCH PLAN  
Instructions for completing the Research Plan are available on the HRPP website.  
The headings on this set of instructions correspond to the headings of the Research Plan.  
General Instructions: Enter a response for all topic headings.  
Enter “Not Applicable” rather than leaving an item blank if the item does not apply to this project.  
Version date: 9/30/2013  
1. PROJECT TITLE  
LinkUP: COVID -19 Intervention for underserved populations  participating in parent study Proyecto La 
Frontera (UCSD IRB #191390).  
2. PRINCIPAL INVESTIGATOR   
Steffanie Strathdee, Ph.D., Distinguished Professor and Harold Simon Chair, Associate Dean of 
Global Health Sciences, Division of Infectious Disease and Global Public Health, UCSD Department 
of Medicine  
 
3. FACILITIES  
The UCSD investigators and staff for this project have offices on the main UCSD campus  (La Jolla 
and 3500 5th Avenue ‘Webster Building’) .  
 
The field operations for the evaluation component of this  study will be carried out in part on the 
streets  of San Diego Count y by UCSD ’s La Frontera  staff.  Operating on a mobile van, this 
component of the study will determine participant eligibility, obtain informed consent, refer consenting participants to our community partner  (OnPoint) , and conduct a prospective evaluation of the LinkUP 
intervention.    
Sera are batched and delivered to Genalyte (San Diego, CA), a CLIA -certified lab that has obtained 
Emergency Use Authorization for their SARS -CoV-2 serology assay.  
 Thi
s project will be conducted in collaboration with a community partner , the Harm Reduction 
Coalition of San Diego (HRCSD) which operates a mobile Syringe Exchange Program (SSP)  called 
OnPoint at 4 locations across San Diego. These 4 locations will be sites where participants  will be 
offered rapid COVID19 antigen and/or SARS -CoV-2 PCR tests  as part of their standard of care, and 
where participants will either receive the active version of the LinkUP intervention (education plus motivational interviewing) or the didactic version of the LinkUP intervention (control condition: education only).  Both versions of the LinkUP intervention, as well as COVID testing , will be 
conducted by staff of OnPoint. Participants opting for SARS -CoV-2 PCR tests , or those testing 
positive on COVID rapid antigen tests will have their  confirmatory PCR tests conducted  by a certified 
lab of the California Department of Public Health (CDPH) . Participants opting for vaccination will be 
referred participants for vaccine to nearby clinics.  Because the H RCSD will be engaged in research 
activities such as administering the LinkUP intervention as part of this project, they will be reliant on UCSD which will serve as the IRB of record for this site, per NIH Single IRB mandate.  
 Data analysis for this study will be conducted by UCSD Staff at the Webster Building in Hillcrest. Analysis of de- identified data will also be conducted by the RADxUP Consortium Data Center at 
Duke University. LinkUP is a part of the RADxUP consortium, which is a network  of U.S. research 
institutions supported by the US National Institutes of Health through the American Recovery Act. RADxUP aims to increase access to COVID19 testing and vaccination among marginalized communities across the US and is attempting to identify  best practices based on information 
collected and shared across the consortium.  The RADxUP Data Coordinating Center is based at Duke University in North Carolina  
 
4. ESTIMATED DURATION OF THE STUDY  
Two years : March 1  2021 - August 30, 2023 . 
 
 
Biomedical IRB Application Instructions  
Page 2  
5. LAY LANGUAGE SUMMARY OR SYNOPSIS (no more than one paragraph)  
Preliminary data from the parent study, La Frontera, have shown that people who inject drugs (PWID) in San 
Diego county are at high risk of COVID -19, yet have very low levels of COVID testing and v accination.  The 
goal of the present study  is to evaluate a pilot intervention (LinkUP) to improve the uptake of COVID -19 testing 
and vaccination among PWID in San Diego County . Results will be shared with RADxUP consortium 
members, policymakers and program planners in California and across the US and used to estimate effect 
sizes for a future efficacy trial. Our study will inform efforts to leverage any of the 185 SSPs around the US as 
‘touchpoints’ to reach marginalized communities, strengthening the nation’s pandemic preparedness 
infrastructure to reduce COVID -19 health disparities . 
 
6. SPECIFIC AIMS  
Together with our community partner, the HRCSD’s OnPoint, a mobile SSP, we will evaluate develop and 
evaluate an intervention to improve uptake of COVID -19 testing and vaccination. Our Study Aims are : 
 
1) To adapt an existing behavioral intervention incorporating motivational interviewing (MI) to improve uptake 
of HIV pre -exposure prophylaxis among people who inject drugs (PWID), by replacing the educational content 
with information intended to improve uptake of COVID19 testing and COVID19 vaccination.   
 2) To pilot test the intervention in Aim 1 (called LinkUP) at OnPoint’s 4 mobile SSP  locations across San Diego 
County . We expect that the LinkUP  intervention will be acceptable to PWID and considered feasible and 
sustainable by OnPoint  staff and the  project’s Community Scientific Advisory Board ( CSAB).    
 
 
7. BACKGROUND AND SIGNIFICANCE  
More than one year into the pandemic, SARS -CoV-2 is becoming endemic. [1] In the US, herd immunity 
against this virus is increasingly being considered  unachievable due to vaccine hesitancy and new circulating 
escape variants. [2, 3]  The implications are enormous: control over COVID- 19 will only become possibl e with 
vaccine equity, which requires an infrastructure to offer COVID- 19 testing, vaccination, boosters and health 
care to the most vulnerable communities. Understanding and overcoming barriers to COVID -19 testing and 
vaccination and developing interventions to improve their uptake is a critical public health priority.  
COVID -19 Testing and Vaccination is Lagging Among PWID.  California has done an admirable job of scaling 
up COVID -19 vaccination. However, like the rest of the country ,[4] vaccine coverage is lower among under -
represented minorities, especially Blac ks and Latinx .[5, 6] To date, in the parent study ( La Frontera ), we h ave 
found that 36% tested sero positive for COVID -19 antibody. Of note, 32% had a COVID test before they joined 
our study, but 65% of those testing SARSCoV- 2 seropositive had not been tested previously , indicating  that 
the ‘worried well’ are those seeking testing, whereas the highest risk PWID are not .[7] Further, despite a 
robust vaccination program  in San Diego County, only 9 % of La Frontera participants had received a COVID 
vaccine as of Sept /21 and only 55% report they were willing to be vaccinated. [8]  Further, we found that beliefs 
in COVID19 conspiracy theories and obtaining most of their COVID19 information from social media were 
independently associated with vaccine hesitancy. [8] 
SSPs are undergoing expansion in CA and elsewhere. Resear ch by our team and others consistently shows 
that syringe exchange programs (SSPs) attract PWID who are at higher risk of acquiring HIV and HCV, [9-12] 
representing a ‘touchpoint’ for those outside the health care system. SSPs are ideally positioned to offer 
ancillary services, such as referrals to substance abuse treatment, overdose prevention, testing for HIV, HCV, STIs and TB, as well as HBV vaccination and PrEP. [13] Mobile SSPs can reach the most vulnerable PWID 
who are homeless and lack transportation. [14] Across the US, states where SSPs can operate legally are 
more likely to offer these services, as well as medical care, [15] but their role in prevention, testing and 
vaccination for COVID -19 has been under -utilized. [16] 185 SSPs operating in the US  have potential as venues 
to reach PWID at high risk of COVID -19.[16] The CDC and C DPH publicly endorse SSPs ,[17, 18]  and SD  
County’s Supervisors recently embraced SSPs in 01/21 .[19] In 2020, CDPH provided funding to 37 SSPs 
 
 
Biomedical IRB Application Instructions  
Page 3 across the state , including our lead community partner, the SD  Harm Reduction Coa lition’s SSP, OnPoint.  The 
CDPH are now offering free rapid COVID- 19 and confirmatory PCR  tests at SSPs across CA as well as free 
COVID -19 vaccinations. However, medical mistrust and vaccine hesitancy are anticipated to be per sistent 
barriers, which our intervention will address. B y basing our intervention at a SSP, we will create a potential 
model for pandemic preparedness that could be replicated at other SSPs to improve COVID testing and 
vaccination, which has been deemed a priority by NASTAD .[16] 
This project is significant because PWID  represent a medically and socially vulnerable population. H igh 
proportions of our study participants are ethnic minorities (75%), homeless (68%), have been in jail/prison (45%)  or are HIV+ (6%) .  Our study te am is uniquely poised to adapt and pilot an appropriate intervention in 
partnership with our established community partner, OnPoint, to encourage uptake of COVID19 testing and vaccination among PWID.  Our prospective parent study, La Frontera,  offers a mechanism to follow -up 
outcomes among PWID who are co- enrolled in LinkUP and compare them to those who are not.  If our LinkUP 
intervention is deemed feasible and acceptable, we plan to apply to the NIH for additional funding to test its efficacy in other SSP locations around the US.  
 
8. PROGRESS REPORT  
N/A    
 
9. RESEARCH DESIGN AND METHODS  
 
La Frontera  Parent Study Infrastructure:  The parent study, La Frontera (R01 DA049644; PI: Strath dee; UCSD 
IRB #191390)  was funded by NIH on 04/1/20 and is  collecting prospective survey data and serology for HIV, 
HCV and SARS -CoV-2 on 600 PWID in both San Diego and Tijuana through 2025. This sub-study (LinkUP)  
will focus only on 150 PWID living in San Diego County based on the following eligibility criteria.  LinkUP is 
funded by NIH through the RADxUP consortium, through the American Recovery Act which was enacted by US Congress in response to the COVID -19 epidemic.  
 Eligibility criteria  fo
 r LinkUP . PWID participati ng in La Frontera were aged 18 or older at their baseline visit in 
2020- 2021, reported living in San Diego County, and injecting drugs within the last month.  All were recruited 
into La Frontera between October 2020 and September 2021.  To be eligible for the LinkUP substudy, subjects 
must be enrolled in La Frontera, report not having ever been tested for COVID -19 outside of La Frontera , and 
report not having had any vaccinations  against COVID -19. They must also have provided consent  to release 
their medical records with the study team , and consent to share  their de- identified data with the RADxUP Data 
Coordinating Center at Duke University . Information on eligibility will be  obtained through participants’  most 
recent interviewer -administered survey in La Frontera . Potentially eligible participants who indicated that they 
are interested in participating will be contacted by La Frontera staff beginning March 1, 2022, at which time 
their eligibility for the LinkUp study will be re -confirmed  using a short interview (screener)  to ensure that their 
eligibility  concerning COVID -19 testing and vaccination has not changed.   
 
Baseline Data Collection.  La Fr ontera staff will obtain written informed consent  in person  from the fi rst 150 
eligible La Frontera participants , who will form the LinkUP study sample.  Consent forms will be offered in both 
English and in Spanish by trained bilingual staff. The LinkUP consent form will include permission to share 
their de -identified data between the OnPoint SSP and our study team.   LinkUP participants whose last La 
Frontera interview was more than 3 months ago will undergo a brief interviewer -administered survey that 
addresses their potential barriers to COVID -19 testing and vaccination (baseline LinkUP survey) .  Measures  
include beliefs and attitudes  to COVID testing and vaccination as well as structural barriers (e.g., lack of 
transportation, homelessness) ; these measures are already approved by the IRB under the parent study ( IRB 
#191390) . Surveys will be conducted by La Frontera’s  interviewers using computer -assisted programmable 
interviewing (CAPI). Interviews are done under canopies outside La Frontera’s mobile van with plexiglass partitions and PPE for both interviewer and participant , as we have done for the La Frontera parent study . 
Interviews will be offered in both Spanish and English by trained bilingual staff. Participants will also undergo 
venipuncture for SARS -Co-V-2 serology.  Following centrifugation, sera are batched and d elivered to Genalyte 
 
 
Biomedical IRB Application Instructions  
Page 4 (San Diego, CA), a CLIA -certified lab that has obtained Emergency Use Authorization for their SARS -CoV-2 
Maverick® Multi -Antigen Serology Panel[20]  and tests for IgM and IgG antibodies against 13 unique viral 
antigens. Sensitivity and specificity for detecting SARS -CoV-2 antibody is 96% and 98% respectively. 
Following the interview and blood draw,  each of the 150 participants will be given a laminated coupon 
indicating the address of the closest OnPoint syringe  exchange loc ation and the program’s schedule and 
encouraged to attend this location at their earliest convenience. All enrolled participants will be provided with 
$20 to reimburse the ir time and the  cost of transportation.  
 
Cluster Randomization. The  four OnPoint syringe exchange locations will be randomized to deliver either the  
active (intervention) or didactic (control) version of the LinkUP intervention. The randomization scheme will be 
developed using an algorithm by La Frontera’s statistician.  Approximately three months into enrollment, there 
will be a one- week ‘washout ’ period, after which time the two original intervention syringe exchange sites will 
become control sites and the two original control sites will become intervention sites. This cluster randomi zation scheme will help ensure that no neighborhood in San Diego County is denied access to the 
LinkUP intervention.  By the end of the study, 75 LinkUP participants will have been randomized to an 
intervention site and 75 will have been randomized to a control site.   
 Participant Intake and O
 ut-take Data at OnPoint Locations . OnPoint peer counselors will confirm that their 
client is a LinkUP participant when they are presented with the laminated card that was provided by LinkUP 
staff.  They will then conduct a short 5 minute interview with the participant to obtain information on their 
COVID testing and vaccination history, their health status and any of their harm reduction needs to facilitate 
any referrals. After their visit, the peer counsellor will supplement this with the Out -take data, which includes 
whether or not the participant received the LinkUP intervention and COVID -19 test(s) . The information 
obtained will be shared through record linkage between OnPoint and La Frontera to  confirm the study 
outcomes .  Following  the intake  interview, the participant will either receive the LinkUP active or didactic 
intervention depending on the randomized allocation of the SSP site.  
 
LinkUP Active i ntervention. The LinkUP intervention will be adapted from an intervention developed by UCSD 
faculty member Dr. Angela Bazzi, who developed an intervention combining education,  motivational 
interviewing (MI) , problem -solving, and ongoing support from peer navigators to increase uptake of and 
adherence to HIV pre -exposure prophylaxis (PrEP) among PWID attending SSPs in Massachusetts. [21, 22]   
The content  of Dr. Bazzi’s PrEP intervention will be replaced with content on COVID -19, including basic 
information on its biology and epidemiology, and the safety and efficacy of available COVID -19 vac cines. This 
information will be drawn from literature shared by our RADxUP consortium leaders and is based on that provided by the CDC. Through an open discussion with one of OnPoint’s peer counselors who are trained in MI, the counselor will  present evidence- based COVID -19 information, which will also address COVID -19 
misinformation (e.g., that COVID is no worse than the flu), and COVID- 19 disinformation (e.g., that COVID 
vaccines include a tracking device). Next, the counselor will attempt to  identify the participant’s concerns about 
COVID -19 and vaccination in an attempt to tip their decisional balance. For example, i n in-depth interviews, 
some participants expressed interest in vaccine only because it protected their loved ones whereas participants who are older or who have co- morbidities like obesity, HIV or diabetes may be more willing to 
consider COVID -19 testing or vaccination if they realize they are at risk of more serious disease.  This session 
will be designed to be completed within 45 minutes.  The LinkUP intervention will be available in English and 
Spanish. Qualified bilingual, bicultural staff will translate and back translate the intervention materials into Spanish.  See Table 1 below for more detailed information on the intervention.   
 
LinkUP Control Condi
 tion (didactic intervention). Given the vulnerability of our population, we plan to offer a 
didactic version of the LinkUP intervention as the control  condition. Like the active version of the intervention 
described above, the didactic component  will be conducted by an OnPoint counselor. They will be instructed to 
answer any questions the participant may have but to not engage in MI counseling.  The same educational 
materials used above will be used for this session and it will be completed within 45 minutes.  See Table 1 
below for more detailed information on the intervention. 
 
 
Biomedical IRB Application Instructions  
Page 5  
Table 1. LinkUP Intervention Components and Example Strategies  
  
Componen
t Examples of Specific Strategies  Mediators  
(a) COVID -
19 Testing 
& Vaccine 
Education*  • Learning about COVID -19 symptoms and testing  
• Debating and debunking local COVID -19 misinformation 
(e.g., vaccine myths)  
• Learning about COVID- 19 vaccines (including efficacy, 
doses, booster Q&A)  
• Identifying where and how to obtain testing and vaccines  Increased COVID -19 
testing & vaccine 
knowledge  
(b) Motivation
al 
Interviewing**   
 • Reviewing factors contributing to local SARS -CoV-2 
transmission, presenting plausible scenarios, adding 
personal meaning incl. personally -relevant risks  
• Rating personal testing and vaccine motivation; discussing 
what could increase it  
• Discussing costs and benefits of testing and becoming fully vaccinated 
• Elaborating on personally -relevant advantages of testing 
and vaccines  
• Aligning COVID knowledge/risk perceptions with testing and vaccine behaviors  Increased COVID -19 
testing & vaccine  
interest & motivation 
(c) Problem -
Solving and 
Planning**   
 • Problem -solving around personally -relevant challenges 
(e.g., competing health or  priorities, schedules, 
homelessness, and other social and structural challenges 
identified by participants in formative research or by 
stakeholders*)  
• Providing enactive mastery experiences (i.e., practicing new skills)  
• Role modeling effective discussions  with peers and 
healthcare providers  
• Handling missed appointments and devising back -up plans  Increased COVID -19 
testing & vaccine  self -
efficacy & behavioral 
skills  
 
(d) Ongoing  
Support ** • As-needed assistance with: (i) planning/scheduling testing 
and vaccine appointments, (ii) attending appointments 
(accompanying if desired); (iii) problem solving around 
new/persistent challenges identified by participant ; (v) 
maintaining cues/reminders for  appointments; (vi) 
obtaining referrals for other health and social services  
• Reinforcement (verbal encouragement) for making, 
following -through on plans  
• Future planning  for ongoing testing and sustained 
vaccination (as needed and recommended, incl. booster s), 
developing systems for continued reminders, identifying external social supports  Reduced structural 
barriers to testing & vaccination  
 
*Given to all participants (i.e., both active and didactic LinkUP intervention arms). **Given to only those participants assigned to a SSP site offering the active LinkUP intervention.  
 
Both interventions will be offered in English or Spanish by trained bilingual staff.  
 
 
 
Biomedical IRB Application Instructions  
Page 6 COVID testing .  The CDPH is  now providing free  rapid COVID -19 antigen tests (BiNaxNow®) [23] to SSPs 
across  California, including OnPoint, This means that SSP clients can access free rapid COVID tests 
regardless of whether or not they are participants in the LinkUP study, as part of their standard of care.     
After  the participant receives either the active or  di dactic LinkUP intervention, the OnPoint peer counselor will 
offer the participant a rapid COVID antigen test , delivered on site at their SSP location.  If the participant 
agrees to testing, it will be accompanied by brief pre- and post -test counseling according to  the CDP H’s 
training module, which is being offered to OnPoint staff in December 2021.  BiNaxNow’s rapid test is conducted 
on a nasal swab and provides results within 15 minutes. Those testing positive will be asked to provide a nasal 
swab for PCR confirmation at a CDPH certified lab. Participants who prefer to have a PCR test instead of a 
rapid test will be permitted to do so.  Participants who receive PCR tests will be asked to provide their contact 
details to permit the counselor to contact them to receive their test results. Subjects testing positive on either 
or both tests will be advised to practice social distancing and when necessary, referred to available resources 
for homeless. Any participant testing positive or who has symptoms consis tent with COVID -19 will be referred 
to the nearest community clinic for free medical care.  
 
COVID -19 vaccination. The CDPH is providing free COVID -19 v accines that have been FDA -approved (i.e., 
Pfizer, Moderna and Janssen) to SSPs across California. Upon completion of the intervention, OnPoint will 
refer participants  for vaccine to nearby clinics.  
 
Participant Reimbursement:  LinkUP participants will be compensated $10 for their visit at OnPoint regardless 
of whether or not they choose to undergo a COVID test or receive a COVID vaccine.  
 
Outcome  Ascertainment:  COVID -19 Testing  & Vaccination. Outcome  ascertainment  will involve  record linkage  
between La Frontera  and OnPoint  to determine which  participants  visited  the SSP site they were  referred  to, 
and if they received the LinkUP  intervention and COVID19  tests. Since  LinkUP  participants  who refuse d 
COVID -19 tests  at the SSPs  and will have  obtained COVID19  vaccination elsewhere, we will obtain these  data 
in three  ways:  1) Self-report  from La Frontera  follow -up interviews  conducted 6 months  after randomization.  2) 
Record linkage with the CDPH’s  COVID -19 database based on electronic  health records  (EHRs ) for 
participants  who provide d a release of medical  information.  Record  linkage will confirm  if and where COVID  
testing  was done  elsewhere,  if COVID -19 vaccine was administered , type,  dates  and # of doses , as well as 
hospitalizations  and deaths.  3) Biological  validation of vaccination will also be done based  on COVID -19 
serology  conducted  by Genalyte,  which  is being  conducted as part of their follow -up visits  in the parent  study,  
La Frontera . 
 
Analysis: Although t he LinkUP trial is  not powered to assess efficacy, we will conduct an intent -to-treat 
analysis following CONSORT guidelines [24] and register it at clinicaltrials.gov before enrolment. We will 
compare socio- demographics across the two study arms (intervention and control) to ensure balance, 
control ling for potential confounders  and study location if there are significant differences. To obtain effect 
sizes and standard error s, percentages  along with 95% CIs for those who a) had a CO VID test within 6 
months of the intervention and b) had ≥ one COVID shot within 6 months of intervention, respectively, will be 
calculated for the two study arms. T o obtain Risk Ratio estimates (intervention/control), we will use a logistic 
regression mixe d model with a) had a COVID test ; and b) had ≥1 COVID shot within 6 months of intervention, 
respectively, as outcomes, considering intervention (active vs. didactic)  as the primary fixed effect , potential 
covariates (e.g., age, gen der, homelessness, income) and a  random intercept for subject. We will also assess 
acceptability and feasibility of the LinkUP intervention among OnPoint investigators,  staff, and clients  through 
focus groups and CSAB meetings.  
 
10. HUMAN SUBJECTS  
Characteristics:  
 
Inclusion Criteria : 
 
 
Biomedical IRB Application Instructions  
Page 7 a) Be enrolled in La Frontera ; 
b) report not having ever been tested for COVID -19 outside of La Frontera ; 
c) not hav ing had any vaccinations against COVID- 19 
d) Provide consent for release of medical records with the study team  
e) Provide consent to share de-i dentified data with the RADxUP Data Coordinating Center at Duke 
University  
 
Exclusion Criteria : 
a) Not enrolled in La Frontera participant;  
b) Report having been tested for COVID- 19 outside of La Frontera ; 
c) Have had any vaccination against COVID -19 
d) Do not provide consent for rele ase of medical records with the study team  
e) Do not provide consent to share de- identified data with the RADxUP Data Coordinating Center at Duke 
University  
f) Participation in other COVID -19 trials  
 
11. RECRUITMENT AND PROCEDURES  PREPARATORY TO RESEARCH  
 
Information on potential eligibility will be obtained through their most recent interviewer -administered survey in 
La Frontera.  Potentially eligible participants who indicated that they are interested in participating will be 
contacted by La Frontera staff beginning March 1, 2022, at which time their eligibility for the LinkUp study will 
be re -confirmed using a short interview (screener) to ensure that their eligibility concerning COVID -19 testing 
and vaccination has not changed.   
 
La Frontera staff will obtain written informed consent in person from the first 150 eligible La Frontera 
participants, who will form the LinkUP study sample. The LinkUP consent form will include permission to share 
their de -identified data between the OnPoint SSP and our study team . The OnPoint IDs are generated using 
1&3 letters of both first and last name, DOB, and a gender identifier M -1, F-2, Other -3. The La Frontera study 
collects all the information used to generate the OnPoint IDs (i.e., names, DOB, and Gender).  However, to 
safeguard confidentiality, the record linkage will be done without using name information (i.e., only based on 
DOB and gender, the combination of which is unique for each LF participant).   
 Link
UP participants will undergo a brief interviewer -administered survey under canopies outside La Frontera’s 
mobile van with plexiglass partitions and PPE for both interviewer and participant.  This protocol has been 
reviewed and approved by UCSD’s office of Environmental Health and Safety . Participants will also undergo 
venipuncture for SARS- Co-V2 serology. Following the interview and blood draw,  the 150  participants will be 
given a laminated coupon indicating the address of one of the 4 OnPoint syringe exchange locations and the program’s schedule and encouraged to attend this location at their earliest convenience. All enrolled 
participants will be provided with $20 to reimburse their time and the cost of transportation.  
 The four OnPoint syringe exchang e locations will be randomized to deliver either the  active (intervention) or 
didactic (control) version of the LinkUP intervention. Approximately three months into enrollment, there will be 
a one- week ‘washout’ period, after which time the two original intervention syringe exchange sites will become 
control sites and the two original control sites will become intervention sites. This  cluster randomization 
scheme will help ensure that no neighborhood in San Diego County is denied access to the LinkUP intervention.  By the end of the study, 75 LinkUP participants will have been randomized to an intervention site and 75 will have been randomized to a control site.  
 
OnPoint peer counselors will confirm that their client is a LinkUP participant when they are presented with the 
laminated card that was provided by LinkUP staff.  They will then conduct a short 5 minute interview with the 
participant to obtain information on their COVID testing and vaccination history, their health status and any of 
their harm reduction needs to facilitate any referrals. After their visit, the peer counsellor will supplement this 
 
 
Biomedical IRB Application Instructions  
Page 8 with the Out -take data, which i ncludes whether or not the participant received the LinkUP intervention, COVID -
19 test(s) . The information obtained will be shared through record linkage between OnPoint and La Frontera to 
confirm the study outcomes  including COVID -19 vaccination.  Following the intake interview, the participant 
will either receive the LinkUP active or didactic intervention depending on the randomized allocation of the 
SSP site.   LinkUP participants will be compensated $10 for their visit at OnPoint regardless of whether or not 
they choose to undergo a COVID test or receive a COVID vaccine.  
 
12. INFORMED CONSENT  
 
La Frontera staff will be responsible for obtaining informed consent. Eligible participants will be informed that  in 
order to participate in the LinkUP study they need to provide consent for release of medical records with the study team, and consent to share their de -identified data with the RADxUP Data Coordinating Center at Duke 
University . In addition, the informed consent form will include information about the intervention and the equal 
probability to be assigned to either the motivational interviewing or didactic component  of the intervention.  
The research staff who will be responsible for obtaining informed consent will assess whether the potential 
participant has understood the study and consent form by asking key questions (e.g., “How much time will this 
take you?”; “What are the possible benefits for you?”). Because it is possible that some of our participants may 
be cognitively impaired, or they may not initially understand the consent process, we will test all potential participants for their comprehension of critical points in the consent form. Errors will be corrected and these 
potential participants will then be asked if they need further clarification. If, after further attempts to clarify any 
misunderstandings, we determine that they may not fully comprehend the critical aspects of the study, they will 
not be enrolled.  The field coordinator will also be available to answer any questions raised by a given 
participant.  If a potential participant decides she or he does not wish to participate, his or her decision will be 
honored regardless of how well they comprehend the study information.  A copy of the consent form without 
any identifiers will be offered to all participants. The consent form includes a description of the study, the 
telephone numbers of  the PIs  where participants can call or leave a message 24 hours a day if they have any 
questions or conce rns.  
 
13. ALTERNATIVES TO STUDY PARTICIPATION  
 
If an eligible La Frontera participant refuses to be participate in LinkUP, the participant will be reassured that 
he/she continues participating in La Frontera. Refusals to participate in LinkUP will be considered a feasibility 
outcome in our intent to treat analysis . Similarly, the CDPH is  providing free rapid COVID -19 antigen tests 
(BiNaxNow®) [23] and free COVID- 19 vaccines that have been FDA -approved (i.e., Pfizer, Moderna and 
Janssen) to SSPs across California, including OnPoint. Therefore, access to these ser vices would still  be 
available to them outside of  LinkUP study participation.  
Counseling services and monitoring and treatment for COVID -19 are also provided at  community clinics in San 
Diego free of charge, regardless of their health insurance status.  
 
14. POTENTIAL RISKS  
 
The most serious risks of the study may include loss of confidentiality. At no time will individual results or 
responses to questions be available to persons outside the study  team and the RADxUP Data 
Coordinating Center.  Data shared with the RADxUP Coordinating Center will not include names. Record 
linkage between On Point and La Frontera will be conducted using non -nominal identifiers, by La 
Frontera’s Data Manager  (See 11. Above for more detailed information) . While  study forms will not 
contain participant’s  name, there is a small chance that someone may discover that a given person 
participated in the LinkUP study. If this were to happen, it could affect a participant’s employability and/or 
insurability , as well as psychological distress, discrimination, and possible victimization. It could also 
include violation of privacy, or possible discomfort/distress. Further mentioned in item 15 are the 
procedures in place to ensure t here is no access to private data beyond the research team.  
 
 
Biomedical IRB Application Instructions  
Page 9  
Other potential risks identif ied include:  
The most commonly expected risks of the study are discussing topics  that might make participants  feel 
uncomfortable or upset. Participants will be reminded that they can ask any of the researchers or OnPoint 
counselors to leave or stop talking to you at any time and participants can change their  mind about 
agreeing to participate in LinkUP even after they  have started. Participan t will also be advised that i f they 
would like to see a counselor after talking with LinkUP staff , they can arrange for that without any cost to 
the participant . 
 If a participant is  are asked to provide a blood specimen because his/her  last La Frontera visit was more 
than 3 months ago, he/she may experience a risk of bruising or discomfort during the procedure. 
However, every precaution will be taken to reduce the risk of the blood draw as our staff is well trained 
and has extensive experience. Participant  will be asked to provide 5-10 cc blood sample (1-2 teaspoons) 
for testing. To date, there have been no reports of participant bruising or discomfort during this procedure 
by our phlebotomists.  
 
Risk of SARSCoV -2 community transmission on study premises: I t is possible that community 
transmission could take place on the study premises while interviewers/counselors are interacting with 
study participants. We will make every attempt to implement control measures: potential participants will be given a face protection device upon entering the premises to be worn at all times while on the study premises and will be requested to wash their hands with soap and water or with hand sanitizer; next, participants will be screened in the open air in the area designated for this purpose with plenty of air flow; 
only two participants will be seen at a given time by study staff: one completing the symptom screening 
questionnaire while the second one is undergoing biological sample collection and testing; both stations will be placed at least 15 feet apart to guarantee social distancing at all times. Study staff will wear face 
protection, N95 masks, nitrile gloves at all times and any other protective equipment deemed necessary. We will also setup clear, plastic screens to provide a physical barrier between study participant and study 
staff while completing the supplemental survey. Upon completion of all study measures, study 
participants will be given an extra facial protection and useful information about SARSCoV -2 preventiv e 
measures and led to the facility’s exit area. We have developed a detailed protocol based on CDC Guidelines for SARSCoV -2 screening in community settings . To date,  over the 24 month period that the 
parent study has been collecting data using this protocol,  there have been no instances of SARSCoV -2 
community transmission on study premises.
 This protocol has been reviewed and approved by UCSD’s 
office of Environmental Health and Safety . 
 
15. RISK MANAGEMENT PROCEDURES AND ADEQUACY OF RESOURCES  
 
Confidentiality of participation:  
Every possible procedure to prevent breach of confidentiality will be taken to ensure there is no access to 
private data beyond the research team. Dr Strathdee in over two decades has never experienced a 
negative incident  with respect to loss of privacy, confidentiality, victimization or psychological distress. We 
will apply  for a Federal Certificate of Confidentiality that will allow us to protect participant information from 
outside requests and subpoenas in the U.S.   
All study staff will be trained not to press participants to answer questions or address issues that seem to be distressing to them, and intervention will be terminated if the participant is overly distressed, fatigued, 
or frustrated by the effort. In the event that clinically significant depression symptoms, suicidality, or other psychiatric conditions are noted, the staff will be instructed to report any incidents or concerns to the field 
coordinator who will arrange for appropriate referral to available mental health referrals in the community .  
 
 
Biomedical IRB Application Instructions  
Page 10  In addition, the PI , all co -investigators , all field study staff  and ONPoint counselors will have completed 
Human Subjects Training and CITI Certification Program  before data collection begins .  
Participant Withdrawal from Study:   
At any time during study participation, staff will carefully minimize calling undue attention to participants to 
maintain their confidentiality and clearly advising them that they may ask the staff to leave/discontinue the 
conversation/interview at any time if they wish so. Participants' wishes and concerns will always be 
immediately respected. Similarly, participants are reminded they have an option not to participate and that 
there are no consequences for not participating.   
 
Communication with Local Authorities  
A signed letter from the principal investigator outlining the study objectives and duration will be sent to 
San Diego police department.  Heightening awareness and ensuring support from local police authorities 
will not only increase safety for participants and study personnel, but will also reassure study participants that their involvement in the study will in no way put them in any danger or lead to harassment by the 
police.  
 
We will implement  SAR
 SCoV-2 transmission control measures  following CDC Guidelines for healthcare 
settings adapted to our study site: potential participants will be given a face protection device upon 
entering the premises to be worn at all times while on the study premises and will be requested to wash 
their hands with soap and water or with hand sanitizer; next, participants will be screened in the open air 
in the area designated for this purpose with plenty of air flow; only two participants will be seen at a gi ven 
time by study staff: one completing the symptom screening questionnaire while the second one is undergoing biological sample collection and testing; both stations will be placed at least 15 feet apart to guarantee social distancing at all times. Study staff will wear face protection, N95 masks, nitrile gloves at 
all times and any other protective equipment deemed necessary. We will also setup clear, plastic screens 
to provide a physical barrier between study participant and study staff while completing the supplemental survey. Upon completion of all study measures, study participants will be given an extra facial protection and useful information about SARSCoV -2 preventive measures and led to the facility’s exit area. We have 
developed a detailed protocol based on CDC Guidelines for SARSCoV -2 screening in com munity 
settings.  
 
16. PRIVACY AND CONFIDENTIALITY CONSIDERATIONS INCLUDING DATA ACCESS AND MANAGEMENT  
 
Our committee structure ensures smooth data collection and communication between UCSD and OnPoint, the 
RADxUP consortium and CDCC. Our Steering Committee  will be co -chaired by Dr. Strathdee and Stamos -
Buesig and will consist of Drs. Patterson and Davey Smith (both Co -Is), and Ms. Abramovitz (Senior 
Statistician). It will meet monthly to review progress towards project milestones, recruitment and follow -up, 
progress reports to CDCC and NIH, manuscripts and dissemination plans and will review potential 
interv entions to propose.  
 
Our Community and Scientific Advisory Board (CSAB) is comprised of 10 community stakeholders and 
scientists not directly involved in LinkUP, at least one of whom has lived experience as PWID. It began 
meeting monthly in Sept 30/21 to review preliminary results from Aim 1 and 2, and recommended the 
appropriate intervention to adapt for LinkUP. Scientists include Peter Davidson, PhD  a harm reduction 
researcher  and UCSD faculty ; Laramie Smith,  PhD a Latinx social psychologist and UCSD fac ulty. 
Community stakeholders include Matt Curtis, from the CDPH, Winston Tilghman, MD from the SDHHS,  
Fatima Munoz, MD, MPH , VP of Research at San Ysidro Health Clinic, Lisa Sylvestro, RN  a nurse-
practitioner at Family Health Centers and Kirin Macapuguay, community organizer and founder of Asian 
Pacific Islander Community Actions. To facilitate cross -site comparisons, we will also include two RADxUP 
collaborators,  Heather Bradley, PhD from Georgia State University who is studying barriers to COVID testing 
 
 
Biomedical IRB Application Instructions  
Page 11  among African Americans, and psychologist  Camille Cioffi , PhD from the Univer sity of Oregon. We also 
include a current OnPoint client , Annie  (last name omitted to protect confidentiality) .  
 
Our Consortium Data Reporting Unit (CDRU)  will be co -chaired by Dr. Patterson and Ms. Abramovitz and will 
also include a dedicated full- time data manager, Ms. Artamanova who has worked with our team for >10 yrs, 
along with Ms. Christensen from OnPoint. CDRU team members will work closely with the RADxSM-UP CDCC 
to harmonize measures and ensure that data are collected and transferred smoothly, adhering to data security 
protocols. Unit members will also participate in CDCC- organized activities, including monthly cross -site 
meetings, cross -site working groups, and dissemination activities to share effective implementation strategies, 
tools and measures. Our semi- annual progress reports will include testing results, barriers and facilitators of 
COVID -19 testing and vaccination, key milestones and challenges to LinkUP implementation.  
Our Human Subjects Unit (HSU ) will monitor ethical and social implications or potential concerns and will be 
co-chaired by Dr. Davey Smith and Ms. Christensen. It will also include Dr. Strathdee and Mr. Vera (La 
Frontera project coordinator). Adverse events will be reported to the HSU and if deemed appropriate, to 
UCSD’s Human Research Protection Program, DSMB, NIH and CDCC (refer to Data Safety and Monitoring 
Plan for details on the DSMB membership and activities).  
 
17. POTENTIAL BENEFITS  
 
Benefits to the subject include free confidential testing and counseling for SARASCoV-2, as well as 
linkage to OnPoint SSP  services, and referrals for COVID -19 vaccination and facilitated referrals for 
medical/social care, in a population that has traditionally been medically underserved. Vaccinations will generate reductions in COVID -19 disease transmission in San Diego which will improve general public 
health. The testing of participants to determine SARS CoV -2 serostatus at follow up visit will potentially 
lead to early identification and early treatment of SARS CoV -2. In addition, voluntary SARS CoV -2 testing 
and counseling has been shown to generate reductions in disease transmission in the community.  Added 
benefits include learning more about COVID -19, demystifying myths surrounding COVID, how to access 
testing and vaccination and possibly, increased individual knowledge may carry some general public 
health benefit consequently.  
 
18. RISK/BENEFIT RATIO  
The direct benefits that subjects can derive from participating in the study are: a) obtaining evidence -
based information on SARSCoV -2 transmission, and testing; b) obtaining results of testing for SARS-
CoV-2; b) obtaining information on disease transmission, treatment, and protection from infection; c) 
information about drug treatment programs in their local community; d) respectful  companionship and 
advocacy for emergency and supportive services by counselors, epidemiologic  survey administrators and 
outreach personnel . Potential significant risks associated with the research are breach of confidentiality 
about study participation or personal information collected in the intervention forms, interview , and testing. 
Since steps are taken by the researcher s to mitigate the probability of the  occurrence of these risks , we 
feel that the potential benefits outweigh the potential risks identified.  
 
19. EXPENSE TO PARTICIPANT  
None other than time taken and, depending on where they live and work, transportation to the clinic.  
 
20. COMPENSATION FOR PARTICIPATION  
 
Quantitative Questionnaire Reimbursement : If a participant joins the LinkUP study and completed their 
last parent study visit more than 3 months  ago, subjects will receive $20 for their LinkUP interview. 
Participants will also receive $10 for their visit to OnPoint. In total, they can receive up to $30 dollars in 
compensation.  
 
 
Biomedical IRB Application Instructions  
Page 12   
21. PRIVILEGES/CERTIFICATIONS/LICENSES AND RESEARCH TEAM RESPONSIBILITIES  
 
Steffanie Strathdee, Ph.D  (PI) an epidemiologist with >20 years’ experience and >650 publications on HIV 
prevention research among PWID, including vaccine studies. [25-28] She was supported through a NIDA 
MERIT Award through May 2021, and was Co- I on the STAHR PWID studies in SD. She has led SSP 
evaluations in Canada, the US and Mexico including a case management intervention based at the Baltimore 
SSP that successfully linked PWID to drug treatment. [29] She is also the PI of La Frontera.  
 
Thomas Patterson, PhD - Co-Investigator , Distinguished Professor, is an HIV prevention scientist with 20 
years’ research on behavioral interventions to reduce risky behaviors among substance users, especially 
using motivational interviewing (MI).  
 
Davey Smith, MD  – Co-Investigator , is an infectious disease physician and director of the Antiviral Research 
Center Lab (AVRC), who is overseeing national COVID- 19 vaccine trials and therapeutics through the ACTIV-
2 adaptive trial.  
  
Angela Bazzi, PhD, MPH  – Co-Investigator, is an Associate Professor in the Herbert Wertheim School 
of Public Health at University of California, San Diego, who has been conducting PrEP intervention 
research with PWID for > 7 years. Dr. Bazzi developed an intervention combing education,  motivational 
interviewing (MI) , problem solving, and peer navigator support to increase uptake of and adherence to PrEP 
among PWID attending SSPs in Massachusetts.  The content of Dr. Bazzi’s PrEP intervention will be replaced 
with content on  COVID -19, including basic information on its biology and epidemiology, and the safety and 
efficacy of available COVID -19 vaccines. Dr Bazzi  will work closely with Dr s. Strathdee and Pat terson on 
the adaptation of the content of the LinkUP intervention.  
 Tara Stamos- Buesig – Subconsortium PI , a harm reduction specialist with training in MI and case 
management, director of OnPoint, established in 2018, member of the Harm Reduction Coalition of SD 
(HRCSD) . As the only mobile, needs -based SSP in SD County, OnPoint provides harm reduction services 
including safer injecting, smoking and safer sex supplies, naloxone and fentanyl test strips. In 2020, they served >1100 clients and attract ~100 new clients each month.  
 
Ann Christensen,  MHS  – Subconsortium Co- Investigator , is a heal th care administration expert who has 
worked with OnPoint since its inception  
. 
 
Alicia Harvey-Vera, MPH, PhD – Project  Director. Dr Vera is fully bilingual and bicultural with an MPH 
and PhD from the Universidad Autonoma de Baja California. She has directed our research projects on 
both sides of the San Diego/Tijuana border for 15 years. She has expertise in both qualitative and 
quantitative data collection with marginalized populations. She will supervise the team’s field work in  
quantitative survey data collection. She will be responsible for the training of interviewers and outreach workers together with Drs. Strathdee and Ms. Stamos ; piloting and revising the study instruments; 
creating protocols for maintaining all study -related documents; overseeing subject screening, 
interviewing, follow -up and daily data transfer; preparing and maintaining human subjects protocols in the 
U.S. and liaising with co-investigators, field staff and policy makers.  
 
Carlos Vera, MPH - Project Coordinator . Dr Vera is fully bilingual and bicultural with an MPH from the 
Universidad Autonoma de Baja California and is also a trained and certified phlebot omist. He has expertise in 
quantitative data collection with marginalized populations as well as clinical trials. He is the project coordinator 
for the parent study (La Frontera) and will supervise the team's quantitative survey data collection for LinkUP,  
 
 
Biomedical IRB Application Instructions  
Page 13  randomization of the subset of participants (N=150) who agree to be recruited into LinkUP, and their follow -up 
(which is conducted as part of La Frontera). He will also translate protocol materials into Spanish and assist in 
the training of peer counselors to deliver the LinkUp intervention together with Drs. Strathdee and Ms. Buesig -
Stamos; piloting and revising the study instruments; creating protocols for maintaining all study -related 
documents; overseeing subject screening, interviewing, follow -up and daily data transfer to Ms. Artamanova at 
the data center; preparing and maintaining human subjects protocols and liaising with co -investigators and field 
staff.  
 
Daniela Abramovitz, M.Sc – Senior statistician . Ms. Abramovitz is a biostatistician who completed all 
the course requirements for a PhD in biostatistics. She has >15 years’ experience in data management 
and analysis and joined our UCSD research team in 2005. She has overseen analyses for all of our San 
Diego and Tijuana studies, and is also well versed in statistical techniques for prospective cohort studies  
and intervention studies, including random effects models, Cox regression, Poisson regression, hierarchical modeling techniques and mediation anal yses. She will oversee Ms. Artamonova’s data 
management and programming of the baseline and follow -up surveys in QDS.  
 
Irina Artamonova, MS. – Quantitative Data Manager.  Ms. Artamonova is a data manager who has 
worked for our binational research team for 7 years. She will be responsible for programming the baseline 
and follow -up surveys in QDS to allow the interviews to be conducted using CAPI. She will also monitor 
the transfer of data collected at the mobile sites and will concatenate data from each timepoint into the 
study’s central database. She will develop a system for tracking participants’ visits and keeping complete 
records, organizing and filing data, and storing consent forms. She will also generate summary data reports and conduct basic statistical analyses under the supervision of Ms. Abramovitz.  
 
 
22. BIBLIOGRAPHY  
 
1. Lavine, J.S., O.N. Bjornstad, and R. Antia, Immunological characteristics govern the transition 
of COVID -19 to endemicity.  Science, 2021. 371 (6530): p. 741- 745. 
2. Aschwanden, C., Five reasons why COVID herd immunity is probably impossible, in Nature. 
2021, Nature. p. 520- 522. 
3. Mandavilli, A. Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe. The New York Times, 2021.  
4. Whiteman, A., et al., Demographic and Social Factors Associated with COVID -19 Vaccination 
Initiation Among Adults Aged ≥65 Years — United States, December 14, 2020– April 10, 2021.  
MMWR Morb Mortal Wkly Rep, 2021.  
5. California For All. Vaccination Progress Data . 2021  [cited 2021 May 5]; Available from: 
https://covid19.ca.gov/vaccination- progress -data/#progress -by-group. 
6. Branch, C.o.S.D. -H.a.H.S.A.- P.H.S. -E.a.I.S. County of San Diego - COVID -19 Vaccination . 
2021  [cited 2021 May 5]; Available from: 
https://sdcounty.maps.arcgis.com/apps/dashboards/c0f4b16356b840478dfdd50d1630ff2a . 
7. Strathdee, S.A., et al., Prevalence and correlates of SARS -CoV-2 seropositivity among people 
who inject drugs in the San Diego- Tijuana border region.  PLoS One, 2021. 16(11): p. 
e0260286.  
8. Strathdee, S., et al., Correlates of COVID -19 Vaccine Hesitancy among People who Inject 
Drugs in the San Diego- Tijuana Border Region.  Clinical Infectious Diseases, 2021: p. ciab975.  
9. Smith, D.M., et al., Predictors of needle exchange program utilization during its implementation and expansion in Tijuana, Mexico.  Am J Addict, 2016. 25 (2): p. 118- 24. 
10. Wood, E., et al., Frequent needle exchange use and HIV incidence in Vancouver, Canada.  Am 
J Med, 2007. 120(2): p. 172 -9. 
 
 
Biomedical IRB Application Instructions  
Page 14  11. Brahmbhatt, H., D. Bigg, and S.A. Strathdee, Characteristics and utilization  patterns of needle -
exchange attendees in Chicago: 1994- 1998.  J Urban Health, 2000. 77(3): p. 346 -58. 
12. Schechter, M.T., et al., Do needle exchange programmes increase the spread of HIV among 
injection drug users?: an investigation of the Vancouver outbr eak. AIDS, 1999. 13(6): p. F45 -
51. 
13. Glick, S.N., et al., The Impact of COVID -19 on Syringe Services Programs in the United 
States. AIDS Behav, 2020. 24(9): p. 2466- 2468.  
14. Riley, E.D., et al., Comparing new participants of a mobile versus a pharmacy -based needle 
exchange program.  J Acquir Immune Defic Syndr, 2000. 24 (1): p. 57 -61. 
15. Jones, C.M., Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S.  Int J Drug Policy, 2019. 70: p. 22 -32. 
16. NASTAD. COVID -19 Vaccine: Guidance for Syringe Sharing Services Programs, Health 
Departments, and People Who Use Drugs . 2021  [cited 2021 May 12]; Available from: 
https://www.nastad.org/resource/covid- 19-v
 accine- guidance- syringe -services- programs -
health- departments -and-people- who-use-0 . 
17. AIDS, C.D.o.P.H.- C.f.I.D.O.o. Guidelines for Syringe Exchange Programs Funded by the 
California Department of Public Health, Office of AIDS . 2021  [cited 2021 May 5]; Available 
from: https://www.cdph .c
 a.gov/Programs/CID/DOA/CDPH%20Document%20Library/Guidelines%20
for%20SEPs_ADA.pdf . 
18. Health, C.D.o.P. Laying a Foundation for Getting to Zero: California's Integrated HIV Surveillence, Prevention, and Care Plan . 2016  [cited 2021 May 5]; Available from:  
https://www.cdph.ca.gov/Programs/CID/DOA/CDPH%20Document%20Library/IP_2016_Final
_ADA.pdf . 
19. Warmth, G. Supervisors approve needle exchange for drug users . The San Diego Tribune, 
2021.  
20. Food and Drug Administration. Maverick™ SARS -CoV-2 Multi -Antigen Serology Panel v2 
01030ART -01.  [cited 2021 May 7]; Available from: 
https://www.fda.gov/media /142915/download . 
21. Bazzi, A.R., et al., Limited Knowledge and Mixed Interest in Pre- Exposure Prophylaxis for HIV 
Prevention Among People Who Inject Drugs.  AIDS Patient Care STDS, 2018. 32(12): p. 529-
537. 
22. Biello, K.B., et al., Perspectives on HIV pr e-exposure prophylaxis (PrEP) utilization and related 
intervention needs among people who inject drugs.  Harm Reduct J, 2018. 15(1): p. 55.  
23. Abbott. BinaxNow™ COVID- 19 Antigen Self Test . 2021  [cited 2021 May 7]; Available from: 
https://www.globalpointofcare.abbott/en/product -detai ls/binaxnow -covid -19-antigen- self-test-
us.html . 
24. Consort Transparent Reporting of Trials. The CONSORT Statement .  [cited 2021 May 12]; 
Available from: http://www.consort -statement.org/ . 
25. Schwarz, K., et al., Positive impact of a shelter -based hepatitis B vaccine program in 
homeless Baltimore children and adolescents.  J Urban Health, 2008. 85(2): p. 228- 38. 
26. Golub, E.T., et al., Changes in willingness to participate in HIV vaccine trials among HIV -
negative injection drug users.  AIDS Behav, 2005. 9 (3): p. 301- 9. 
27. Kuo, I., et al., Poor validity of self -reported hepatitis B virus infection and vaccination status 
among young drug users.  Clin Infect Dis, 2004. 38 (4): p. 587- 90. 
28. Kuo, I., et al., Hepatitis B virus infection and vaccination among young injection and non-
injection drug user s: missed opportunities to prevent infection.  Drug Alcohol Depend, 2004. 
73(1): p. 69 -78. 
 
 
Biomedical IRB Application Instructions  
Page 15  29. Strathdee, S.A., et al., Facilitating entry into drug treatment among injection drug users 
referred from a needle exchange program: Results from a community -based behavioral 
intervention trial.  Drug Alcohol Depend, 2006. 83(3): p. 225- 32. 
 
23. FUNDING SUPPORT FOR THIS STUDY  
 
The main study is funded by the National Institutes of Health (NIH) – National Institute of Drug Abuse 
(NIDA) (R01 DA049644).  The grant’s project period is from 04/01/2020 until 01/31/2025. This project is 
also funded by a competitive revision through the RADxUP program, which itself is funded by the 
American Recovery Act under a congressional mandate.  The RADxUP project period i s from 09/01/2021-
08/31/2023. The fiscal contact person for both of these projects  is Mr . William Gentz 
wgentz@health.ucsd.edu .  
 
24. BIOLOGICAL MATERIALS TRANSFER AGREEMENT  
Transfer protocols will be worked out between field staff in Tijuana , field staff in San Diego , and the 
UCSD CFAR laboratory , Genalyte Laboratory, and CDC Laboratory  to ensure the safe storage and timely 
testing of biosamples.  
 
25. INVESTIGATIONAL DRUG FACT SHEET AND IND/IDE HOLDER  
Not applicable.  
 
26. IMPACT ON NURSING STAFF  
Not applicable.  
 
27. CONFLICT OF INTEREST  
The researchers involved in the study do not have any conflict of interest.  
 
28. SUPPLEMENTAL INSTRUCTIONS FOR CANCER -RELATED STUDIES  
Not applicable .  
 
29. OTHER APPROVALS/REGULATED MATERIALS  
Not applicable .  
 
30. PROCEDURES FOR SURROGATE CONSENT AND/OR DECISIONAL CAPACITY ASSESSMENT  
The research staff who will be responsible for obtaining informed consent will assess whether the 
potential participant has understood the study and consent form by asking key questions (e.g., “How 
much time will this take you?”; “What are the possible benefits for you?”). Because it is possible that some 
of our participants may be cognitively impaired, or they may not initially understand the consent process, we will test all potential participants for their comprehension of critical points in the consent form. Errors will be corrected and these potential participants will then be asked if they need further clarification. If, after further attempts to clarify any misunderstandings, we determine that they may not fully comprehend 
the critical aspects of the study, they will not be enrolled. If a potential participant decides she or he does not wish to participate, his or her decision will be honored regardless of how well they comprehend the 
study information.  
 
 